News

Funding for the device was thanks to companies like Nike and the Oregon ToughTech Breakthrough Fund.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

Yasha Modi, MD, spoke with Modern Retina about the ASRS 2024: The DAVIO phase 2 trial and upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.

Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

Michael Singer, MD, presented 100-week results from the RESTORE trial and shares key takeaways from his presentation at this year's American Society of Retina Specialists (ASRS) meeting.

Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024

Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial

A recent study found that adolescents with myopia were twice as likely to develop anxiety and mood disorders.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

TFI employs spectral interference technology to image and map the corneal surface.

Jordana Fein, MD, MS, spoke with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.

Riaz Qureshi, PhD, explains the effects of spin sneaking into systematic reviews and ways the scientific community can better identify it to improve the validity.

Stephen Russell, MD, discussed his presentation on safety and durability of voretigene neparvovec-rzyl for biallelic RPE65 at the annual ASRS meeting in Stockholm, Sweden.

Charles Wykoff, MD, PhD, gives an insight into first-time data from the phase 2, LUNA trial looking at Ixo-Vec at the annual ASRS meeting in Stockholm, Sweden.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

Eleonora Lad, MD, PhD, discusses multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD

Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.

The professor was recently given the award for his contributions to advancing vitreoretinal surgery, treatment, research, and patient care.

Alan Franklin, MD, PhD, FASRS, a retina specialist in Mobile, Alabama spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage."

Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

Sally S. Ong, MD, spoke with Modern Retina about her research titled, "Individual and neighborhood-level socioeconomic characteristics associated with presenting visual acuity and foveal status in rhegmatogenous retinal detachment" at the annual ASRS meeting in Stockholm, Sweden.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Ashkan Abbey, MD, spoke with Modern Retina about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.